How to buy Alnylam Pharmaceuticals stock | 131.05

Alnylam Pharmaceuticals, Inc is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,323 staff and has a trailing 12-month revenue of around USD$345.2 million.

How to buy shares in Alnylam Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Alnylam Pharmaceuticals. Find the stock by name or ticker symbol: ALNY. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alnylam Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$131.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alnylam Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Alnylam Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Alnylam Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Alnylam Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$131.05, which is 0.02% up on its pre-crash value of USD$131.03 and 54.23% up on the lowest point reached during the March crash when the shares fell as low as USD$84.97.

If you had bought USD$1,000 worth of Alnylam Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$863.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,142.76.

Alnylam Pharmaceuticals share price

Use our graph to track the performance of ALNY stocks over time.

Alnylam Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$131.05
52-week range	USD$84.97 - USD$167.33
50-day moving average	USD$135.9794
200-day moving average	USD$139.4904
Wall St. target price	USD$163.78
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-8.254

Buy Alnylam Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Alnylam Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alnylam Pharmaceuticals price performance over time

Historical closes compared with the close of $131.05 from 2020-11-16

1 week (2020-11-17)	1.35%
1 month (2020-10-27)	3.34%
3 months (2020-08-25)	-2.27%
6 months (2020-05-23)	N/A

1 year (2019-11-25)	16.57%
2 years (2018-11-23)	78.69%
3 years (2017-11-24)	-1.35%
5 years (2015-11-25)	24.51%

Alnylam Pharmaceuticals financials

Revenue TTM	USD$345.2 million
Gross profit TTM	USD$194.7 million
Return on assets TTM	-18.95%
Return on equity TTM	-53.61%
Profit margin	-245.14%
Book value	$12.103
Market capitalisation	USD$16.3 billion

TTM: trailing 12 months

Shorting Alnylam Pharmaceuticals shares

There are currently 3.3 million Alnylam Pharmaceuticals shares held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 9.1% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals shares can be evaluated.

Alnylam Pharmaceuticals's "short interest ratio" (SIR)

Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals shares currently shorted divided by the average quantity of Alnylam Pharmaceuticals shares traded daily (recently around 549621.92242833). Alnylam Pharmaceuticals's SIR currently stands at 5.93. In other words for every 100,000 Alnylam Pharmaceuticals shares traded daily on the market, roughly 5930 shares are currently held short.

However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals shares, or, against the total number of tradable Alnylam Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Alnylam Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0388% of the tradable shares (for every 100,000 tradable Alnylam Pharmaceuticals shares, roughly 39 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.

Find out more about how you can short Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals share dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.

Alnylam Pharmaceuticals share price volatility

Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $84.97 up to $167.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.4892. This would suggest that Alnylam Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Alnylam Pharmaceuticals is owned by insiders or institutions?

  Currently 0.801% of Alnylam Pharmaceuticals shares are held by insiders and 94.741% by institutions.

• How many people work for Alnylam Pharmaceuticals?

  Latest data suggests 1,323 work at Alnylam Pharmaceuticals.

• When does the fiscal year end for Alnylam Pharmaceuticals?

  Alnylam Pharmaceuticals's fiscal year ends in December.

• Where is Alnylam Pharmaceuticals based?

  Alnylam Pharmaceuticals's address is: 675 West Kendall Street, Cambridge, MA, United States, 02142

• What is Alnylam Pharmaceuticals's ISIN number?

  Alnylam Pharmaceuticals's international securities identification number is: US02043Q1076

• What is Alnylam Pharmaceuticals's CUSIP number?

  Alnylam Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 02043Q107